Adezmapimod (hydrochloride) - HY-10256A
Nur noch %1 verfügbar
Catalog #
HY-10256A
Ab
42,00 €
Adezmapimod (SB 203580; RWJ 64809) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride does not disrupt JNK activity and is an autophagy and mitophagy activator[1].
| Datasheet URL | http://file.medchemexpress.com/batch_PDF/HY-10256A/Adezmapimod-hydrochloride-DataSheet-MedChemExpress.pdf |
|---|---|
| Shipping | Room Temperature |
| Application | COVID-19-immunoregulation |
| Alternative Names | SB 203580 (hydrochloride); RWJ 64809 (hydrochloride) |
| CAS | 869185-85-3 |
| Storage | 4°C (Powder, sealed storage, away from moisture) |
| MWT | 413.90 |
| Solubility | DMSO : 100 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic) |
| Clinical Information | No Development Reported |
| Target | Autophagy;Mitophagy;Organoid;p38 MAPK |
| Application: | COVID-19-immunoregulation |
|---|